Fermenta Biotech Limited (FERMENTA)
₹474.35 +5.48% இன்றைய முடிவு விலை
சுருக்கம்
Fermenta Biotech Limited closed at ₹474.35 on 12 Nov 2026, with an RSI(14) of 53.9 and a P/E of 24.71. On the daily chart it is in a range, with a technical score of 34/100 (bearish). In the quarter ended September 2026, revenue grew 1.9% and net profit fell 47.7% from a year earlier. Data as of 12 Nov 2026.
விலை
- விலை
- ₹474.35
- நாள் மாற்றம்
- +5.48%
- சந்தை மதிப்பு
- ₹1,360 கோடி
- 52-வார வரம்பு
- ₹248.85 – ₹582.65
- 52-வார உச்சத்திலிருந்து
- -18.59%
- 52-வார தாழ்விலிருந்து
- +90.62%
டெக்னிக்கல்ஸ்12 நவ. 2026
- போக்கு
- வரம்பு
- தொழில்நுட்ப மதிப்பெண்
- 34/100 · Bearish
- MACD
- ஏற்றத்துக்கு சாதகமான (bullish)
- RSI (14)
- 53.93
- ADX (14)
- 27.82
- SuperTrend
- இறக்கத்துக்கு சாதகமான (bearish)
- 20-நாள் SMA-உடன் ஒப்பீடு
- +5.34%
- 50-நாள் SMA-உடன் ஒப்பீடு
- -1.64%
- RS மதிப்பீடு
- 81.00
- அருகிலுள்ள சப்போர்ட்
- ₹436.20
- அருகிலுள்ள ரெசிஸ்டன்ஸ்
- ₹479.45
நிதிநிலை12 நவ. 2026
- P/E
- 24.71
- P/B
- 3.25
- ROE
- 13.2%
- கடன்-டு-ஈக்விட்டி
- 0.26
- OPM
- 17.5%
- YoY காலாண்டு விற்பனை வளர்ச்சி
- 1.9%
- YoY காலாண்டு லாப வளர்ச்சி
- -47.7%
சமீபத்திய காலாண்டு செப். 2026 · ஒருங்கிணைந்த
பங்குச் சந்தை செயல்பாடு12 நவ. 2026
- டெலிவரி
- 46.79% எதிர் சராசரி 42.26%
- வால்யூம் அதன் சராசரியுடன் ஒப்பீடு
- 0.6×
- பல்க் & பிளாக் டீல்கள்
- 60 நாட்களில் 7
- இன்சைடர் வர்த்தகம்
- 90 நாட்களில் 5 அறிவிப்பு; சந்தையில் நிகர விற்பனை ₹57.7 கோடி
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- Q2 FY27, தாக்கல் செய்யப்பட்டது 5 நவ. 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 5 நவ. 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
Fermenta Biotech Limited Q2 FY27 காலாண்டு முடிவுகளை 5 நவ. 2026 அன்று வெளியிட்டது: வருவாய் ₹133 கோடி (ஆண்டு அடிப்படையில் +1.9%, முந்தைய காலாண்டை விட +18.6%), நிகர லாபம் ₹9.4 கோடி (ஆண்டு அடிப்படையில் -47.7%); செயல்பாட்டு லாப வரம்பு 15.2%.
| Q2 FY27 (₹ கோடி) | மதிப்பு | YoY Q2 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹133 | +1.9% | +18.6% |
| செயல்பாட்டு லாபம் | ₹20.1 | -24.5% | -12.5% |
| நிகர லாபம் | ₹9.4 | -47.7% | -37.0% |
| EPS (₹) | 3.40 | -44.6% | -35.0% |
| செயல்பாட்டு லாப வரம்பு | 15.2% | — | — |
- லாபம் அதன் சொந்தப் போக்கை விட -16% கீழே
- செயல்பாட்டு லாப வரம்பு 530 bps YoY குறைந்தது
லாபத்தின் தரம்: வரிக்கு முந்தைய ₹14.2 கோடி லாபத்தில், ₹11.2 கோடி (78%) முக்கிய வணிகத்திலிருந்து வந்தது; மீதம் பிற வருமானம் மற்றும் ஒருமுறை வரவுகளிலிருந்து வந்தது. முக்கிய லாபம் (செயல்பாட்டு லாபத்தில் வட்டி மற்றும் தேய்மானத்தைக் கழித்தது) YoY அடிப்படையில் -40.1% மாறியுள்ளது.
அதன் சொந்தப் போக்குக்கு எதிராக: நிகர லாபம் ₹9.4 கோடியாக இருந்தது; இது, அதன் சமீபத்திய வளர்ச்சி சுட்டிக்காட்டிய ₹11.3 கோடியுடன் ஒப்பிடும்போது -16.4% ஆகும் (below trend). இது ஒரு புள்ளியியல் அடிப்படை மட்டுமே; ஆய்வாளர் மதிப்பீடு அல்ல.
முடிவுகள் வெளியானதிலிருந்து பங்கு விலை: +7.9% (அறிவிப்புக்கு முந்தைய முடிவு விலை முதல் சமீபத்திய முடிவு விலை வரை).
FERMENTA delivery percentage and bulk deals
க்கான NSE EOD தரவு
On Thu, 12 Nov 2026, 46.79% of the FERMENTA shares traded on NSE were taken to delivery, against the stock's own 20-session average of 42.26%. That is close to its usual level. 7 bulk or block deals were reported in FERMENTA in the last 60 days: ₹40 Cr bought and ₹73 Cr sold.
கடந்த 5 அமர்வுகளில் டெலிவரி: 33.4% · 24.2% · 52.7% · 42.1% · 46.8%
| தேதி | பக்கம் | எதிர்தரப்பு | மதிப்பு | விலை | அளவு | வகை |
|---|---|---|---|---|---|---|
| 29 செப். | விற்க | Alphagrep Securities Private Limited | ₹9.14 கோடி | ₹547.97 | 166,836 | பல்க் |
| 29 செப். | வாங்கு | Alphagrep Securities Private Limited | ₹9.14 கோடி | ₹547.61 | 166,836 | பல்க் |
| 29 செப். | விற்க | Qe Securities Llp | ₹8.06 கோடி | ₹547.11 | 147,373 | பல்க் |
| 29 செப். | வாங்கு | Qe Securities Llp | ₹7.94 கோடி | ₹551.69 | 143,855 | பல்க் |
| 28 செப். | விற்க | Thakkar Preeti | ₹55.34 கோடி | ₹474.65 | 1,165,938 | பல்க் |
பங்குச் சந்தை வெளியிட்டவற்றின் விளக்கம், பரிந்துரை அல்ல. "accumulation" அல்லது "லாங் பில்டப்" போன்ற பெயர்கள் எண்களில் உள்ள ஒரு வடிவத்தை குறிக்கின்றன. டெலிவரி எவ்வாறு பகுப்பாய்வு செய்யப்படுகிறது
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Fermenta Biotech released its Q2/H1 FY27 earnings presentation, showing Q2 revenue flat at ₹135.8 crore (up 0.1% YoY, up 8% QoQ) and PAT down 48% YoY to ₹9.4 crore. For H1 FY27, revenue dropped 7% YoY to ₹261.9 crore while PAT declined 52% YoY to ₹18.9 crore, driven by a sharp price and volume reset in Vitamin D3 animal nutrition. However, operating cash flow for H1 improved by 44% to ₹54.8 crore due to working capital release, keeping net debt minimal at under ₹3 crore. Management is focusing on product innovation, including plant-based VITADEE Green scale-up backed by a ₹60 crore Dahej capex with capacity expected in Q2 FY28.
- Q2 FY27 PAT fell 48% YoY to ₹9.4 crore, while EBITDA declined 28% YoY to ₹23.2 crore
- Animal nutrition revenue dropped to ₹22 crore in H1 FY27 from ₹46 crore in H1 FY26 (volumes down 31%, realisations down 35%)
- Operating cash flow rose 44% YoY to ₹54.8 crore for H1 FY27, bringing net debt below ₹3 crore
- VITADEE Green commercial capacity is slated for Q2 FY28 within an approved ₹60 crore Dahej capex
Fermenta Biotech reported a 7% YoY decline in consolidated revenue to ₹261.9 crore for H1FY27, while EBITDA fell 34% YoY to ₹45.6 crore and PAT dropped 52% YoY to ₹18.9 crore. The downturn was primarily driven by the Vitamin D3 Animal Nutrition segment, where sales dropped 52% YoY to ₹22.1 crore due to lower volumes and a 35% decline in realizations. For Q2FY27, revenue was flat at ₹135.8 crore (+0.1% YoY, +8% QoQ) and PAT fell 48% YoY to ₹9.4 crore. Positively, the Human Nutrition segment rose to approximately two-thirds of revenue, and India's revenue contribution expanded to 51% from 40% a year earlier.
- H1FY27 consolidated revenue down 7% YoY to ₹261.9 crore; Q2FY27 revenue flat at ₹135.8 crore
- H1FY27 PAT halved, dropping 52% YoY to ₹18.9 crore, with diluted EPS at ₹6.67
- Vitamin D3 Animal Nutrition revenue tumbled 52% YoY to ₹22.1 crore on a 35% decline in realizations and 31% volume drop
- Vitamin D3 Human Nutrition grew 2% YoY to ₹162.5 crore, forming nearly two-thirds of total revenue
- German, US, and Environment subsidiaries reported H1FY27 EBITDA losses of ₹2.5 crore, ₹1.0 crore, and ₹4.7 crore respectively
Fermenta Biotech Limited's Board of Directors has approved the closure of its non-material, wholly-owned subsidiary, Fermenta Biotech (UK) Limited. The UK entity has had no operations for several years, generating nil revenue and reporting a nominal loss of £1,260 with net assets of £30,231 in FY26. European operations continue to be handled through an active operating subsidiary in Germany (Fermenta Biotech GmbH). The closure is intended to streamline the corporate structure and lower administrative and compliance costs.
- Board approved closure of wholly-owned subsidiary Fermenta Biotech (UK) Limited under UK law
- FBL UK contributed nil revenue/turnover in FY 2025-26
- Net loss of £ 1,260 and net assets of £ 30,231 (primarily cash at bank) in FY 2025-26
- Entity originally acquired on September 10, 2002; inactive post-Brexit as EU operations shifted to German subsidiary
Fermenta Biotech reported standalone revenue from operations of ₹116.94 Cr for the quarter ended September 30, 2026, up 9.2% YoY compared to ₹107.12 Cr in Q2 FY26. Standalone profit after tax (PAT) came in at ₹13.95 Cr, registering a decline of 5.2% YoY from ₹14.72 Cr and down 6.9% QoQ from ₹14.99 Cr. Basic EPS for the quarter was ₹4.86 compared to ₹5.05 in the year-ago period. Additionally, the company recognized its 'Environment' business as a separate reportable segment under Ind AS 108.
- Standalone revenue from operations rose 9.2% YoY to ₹11,693.63 Lakhs (₹116.94 Cr)
- Standalone PAT declined 5.2% YoY to ₹1,395.36 Lakhs (₹13.95 Cr)
- H1 standalone revenue stood at ₹22,877.56 Lakhs with PAT at ₹2,893.94 Lakhs
- Diluted EPS for the quarter came in at ₹4.77 versus ₹5.01 in Q2 FY26
- Subsidiary FESPL raised ₹21.53 Lakhs (25% subscription) via private placement of 7,17,949 shares at ₹12 each
Fermenta Biotech Limited submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the period ended September 30, 2026. The confirmation, issued by Registrar and Transfer Agent MUFG Intime India Pvt. Ltd. on October 7, 2026, certifies that all physical share certificates received for dematerialisation were processed, verified, and cancelled within prescribed timelines. The RTA also noted that zero rematerialization requests were received during the quarter. This is a recurring regulatory disclosure with no impact on operations or financials.
- Compliance certificate submitted for the quarter ended September 30, 2026
- RTA confirmation issued by MUFG Intime India Pvt. Ltd. dated October 7, 2026
- Confirmation that zero requests were received for rematerialization during the quarter
- Filing submitted to BSE and NSE on October 08, 2026
Fermenta Biotech Limited has informed the exchanges that its officials will participate in a physical one-to-one investor meeting in Mumbai on September 22, 2026. The discussions will be based on already public press releases and investor presentations, with no unpublished price-sensitive information (UPSI) shared. In its latest reported quarter (Jun 2026), the company posted revenue of Rs 111.84 cr and net profit of Rs 14.99 cr. This disclosure is a standard regulatory intimation under Regulation 30 of SEBI LODR.
- One-to-one investor meeting scheduled for September 22, 2026
- Meeting to be held physically in Mumbai
- No unpublished price sensitive information (UPSI) will be discussed
- Jun 2026 quarterly revenue stood at Rs 111.84 cr with net profit of Rs 14.99 cr
Fermenta Biotech Limited has dispatched reminder letters to shareholders who have not claimed dividends for seven consecutive years starting from the FY 2019-20 interim dividend. Concerned shareholders must submit their claims on or before November 18, 2026. Failing this, the underlying shares and unpaid dividends will be transferred to the Investor Education and Protection Fund (IEPF) Demat Account under Section 124(6) of the Companies Act, 2013.
- Notice dispatched on September 16, 2026 to shareholders with unclaimed dividends for 7 consecutive years.
- Deadline set to November 18, 2026 for shareholders to claim unpaid dividends before shares transfer to IEPF.
- Applies to unpaid interim dividends starting from the financial year 2019-20.
- Action mandated under Section 124(6) of the Companies Act, 2013 and IEPF Rules, 2016.
Fermenta Biotech Limited has signed an exclusive licensing agreement with Vellore Institute of Technology (VIT) for commercialising an in-situ Vitamin B12 fortification technology in fermented foods (Indian Patent Application No. 202441015300). Lab studies indicated approximately 80% retention of Vitamin B12 post-cooking. Financial terms, including licensing fees or commercialization royalty figures, were not disclosed. The development represents an early-stage technological expansion of Fermenta's nutritional premix and food fortification portfolio.
- Exclusive licence agreement with VIT Vellore for Vitamin B12 fortification technology covered under Indian Patent Application No. 202441015300
- Laboratory studies demonstrated approximately 80% retention of enhanced Vitamin B12 post-cooking
- Financial licensing fees, royalty rates, and commercialisation capex are not disclosed
- Company reported Jun 2026 quarterly revenue of ₹111.84 cr and net profit of ₹14.99 cr
Fermenta Biotech Limited resubmitted its standalone and consolidated unaudited financial results for the quarter ended June 30, 2026, in a machine-readable format following an exchange query. The company had initially approved and reported these results on August 11, 2026. For Q1 FY27, standalone revenue from operations stood at ₹11,183.93 lakhs (down 6.0% YoY from ₹11,901.87 lakhs), while standalone net profit was ₹1,498.58 lakhs compared to ₹1,623.38 lakhs in the corresponding prior-year period. Statutory auditors M/s SRBC & Co. LLP issued a limited review report with an unmodified conclusion.
- Resubmission of Q1 FY27 financial results in machine-readable format as requested by the exchange on September 03, 2026
- Standalone revenue from operations reported at ₹11,183.93 lakhs for the quarter ended June 30, 2026 (vs ₹11,901.87 lakhs in Q1 FY26)
- Standalone profit after tax stood at ₹1,498.58 lakhs with basic EPS of ₹5.23 per share of ₹5 face value
- Company granted 3,95,400 employee stock options at an exercise price of ₹83.67 per option during the quarter
- Auditor SRBC & Co. LLP issued an unmodified review conclusion on both standalone and consolidated results
Fermenta Biotech Limited has informed the stock exchanges that company officials will participate in physical one-on-one investor meetings in Mumbai on September 3, 2026. The company stated that discussions will be based on already published press releases and investor presentations available in the public domain. No unpublished price sensitive information (UPSI) will be shared during the interaction.
- Investor meeting scheduled for September 3, 2026 in Mumbai
- Format is physical one-to-one meeting(s)
- No unpublished price sensitive information (UPSI) to be shared
- Discussions to rely on existing public presentations and filings
Fermenta Biotech Limited has informed the exchanges regarding a scheduled one-to-one physical meeting with investor(s) on August 21, 2026, in Mumbai. The company clarified that discussions will rely on publicly available presentations and press releases, with no unpublished price-sensitive information (UPSI) shared. In its latest reported quarter (June 2026), the company posted revenue of ₹111.84 cr and a net profit of ₹14.99 cr.
- One-to-one physical investor meeting scheduled for August 21, 2026, in Mumbai
- Company confirmed no Unpublished Price Sensitive Information (UPSI) will be discussed
- Latest June 2026 quarter reported revenue of ₹111.84 cr and PAT of ₹14.99 cr
Fermenta Biotech Limited has received a credit rating upgrade from CARE Ratings Limited across its bank facilities totaling Rs 172.98 crore. Long-term bank facilities of Rs 166.73 crore (enhanced from Rs 118.94 crore) were upgraded to CARE BBB+; Stable from CARE BBB; Stable. Short-term bank facilities of Rs 6.25 crore were upgraded to CARE A2 from CARE A3+. The rating enhancement indicates improved operational and credit profile, potentially aiding in better borrowing terms.
- Long-term bank facilities rating upgraded to CARE BBB+; Stable from CARE BBB; Stable
- Long-term bank facilities limit enhanced to Rs 166.73 crore from Rs 118.94 crore
- Short-term bank facilities of Rs 6.25 crore upgraded to CARE A2 from CARE A3+
- Total rated bank facilities increased to Rs 172.98 crore
Fermenta Biotech Limited held its 74th Annual General Meeting on August 11, 2026, where shareholders approved a dividend of ₹3.75 per share (75% of face value). A key resolution passed includes the approval of material related party transactions with its step-down subsidiary, Fermenta USA LLC, for an aggregate value up to ₹100 crores. The company also authorized the payment of commissions to non-executive directors, capped at 1% of net profits. All proposed resolutions, including the re-appointment of Director Ms. Rajeshwari Datla, were passed with the requisite majority.
- Approved a dividend of ₹3.75 per equity share (75% of ₹5 face value) for FY 2025-26.
- Authorized material related party transactions with Fermenta USA LLC up to a limit of ₹100 crores.
- Capped commissions for Non-Executive Directors at 1% of the company's net profits.
- Set the dividend payment deadline for on or before August 21, 2026.
- Confirmed the re-appointment and continuation of Ms. Rajeshwari Datla as a Non-Executive Director.
Fermenta Biotech Limited concluded its 74th Annual General Meeting on August 11, 2026, with shareholders approving all proposed resolutions with overwhelming majorities. A key highlight is the approval of a Rs 3.75 per equity share dividend (75% of face value) for FY26. Shareholders also ratified the audited standalone and consolidated financial statements for the year ended March 31, 2026. Additionally, approval was granted for material related party transactions and the re-appointment of Ms. Rajeshwari Datla as a Non-Executive Director.
- Dividend of Rs 3.75 per equity share (75% of Rs 5 face value) approved for FY26.
- Material Related Party Transactions resolution passed with 99.9763% votes in favor.
- FY26 Standalone and Consolidated Financial Statements adopted with 99.9999% shareholder approval.
- Re-appointment of Ms. Rajeshwari Datla as Director approved with 99.9980% majority.
- AGM conducted virtually, concluding at 5:12 p.m. IST on August 11, 2026.
Fermenta Biotech reported a weak YoY performance for Q1 FY27, with PAT falling 56% to INR 9.5 crore, largely due to a high base in Q1 FY26 which included non-recurring income. Revenue stood at INR 126.2 crore, down 13% YoY, though the Human Nutrition segment showed sequential recovery with 24% QoQ growth to INR 76.5 crore. The company is pivoting toward the domestic market, with India now contributing 47% of revenue compared to 35% a year ago. Animal nutrition remains a significant drag, with volumes down 52% QoQ as the company maintained volume discipline against a 40% drop in realizations.
- Human Nutrition revenue grew 24% QoQ to INR 76.5 crore, with segment volumes increasing 18% QoQ.
- Animal Nutrition revenue fell 41% YoY to INR 12.6 crore, impacted by a 40% drop in average realizations.
- India's share of consolidated revenue increased to 47% in Q1 FY27 from 35% in Q1 FY26.
- Raw material costs improved to 35% of revenue, down from 37% in FY26 and 38% in FY25.
- Employee costs rose to 19% of revenue from 16% in FY26, reflecting capacity expansion ahead of Dahej scale-up.
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
